What is HC Wainwright’s Estimate for Belite Bio Q3 Earnings?

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Research analysts at HC Wainwright lifted their Q3 2025 earnings estimates for shares of Belite Bio in a research report issued to clients and investors on Monday, September 15th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.52) per share for the quarter, up from their previous forecast of ($0.53). HC Wainwright currently has a “Buy” rating and a $98.00 target price on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio’s Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.97) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.47) EPS and FY2026 earnings at ($1.92) EPS.

Belite Bio (NASDAQ:BLTE) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.03). During the same period in the prior year, the business posted ($0.31) EPS.

Separately, Wall Street Zen lowered shares of Belite Bio from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $96.00.

Belite Bio Trading Up 9.1%

NASDAQ:BLTE opened at $73.00 on Wednesday. Belite Bio has a 1 year low of $43.70 and a 1 year high of $86.53. The firm’s fifty day simple moving average is $65.31 and its 200 day simple moving average is $62.97. The firm has a market capitalization of $2.32 billion, a PE ratio of -47.10 and a beta of -1.50.

Institutional Trading of Belite Bio

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its position in Belite Bio by 43.3% in the 1st quarter. GAMMA Investing LLC now owns 1,849 shares of the company’s stock worth $122,000 after purchasing an additional 559 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in Belite Bio in the 4th quarter worth $155,000. EverSource Wealth Advisors LLC acquired a new stake in Belite Bio in the 2nd quarter worth $147,000. Bank of America Corp DE grew its position in Belite Bio by 36.4% in the 4th quarter. Bank of America Corp DE now owns 18,342 shares of the company’s stock worth $1,157,000 after purchasing an additional 4,891 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Belite Bio during the 2nd quarter worth about $547,000. 0.53% of the stock is currently owned by institutional investors and hedge funds.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.